Arcellx
Updated: January 13, 2026
David Hilbert - President & CEO
Country: USA | Funding: $622M (+)
Founded: 2015
Website: https://www.arcellx.com/
Arcellx develops cell-based therapies for cancer treatment, based on immune cells that can be easily suppressed, activated and reprogrammed throughout the disease course. The company has developed D-domain - small, stable, fully synthetic binding protein with a hydrophobic core that serves as a chimeric antigen receptor, potentially enabling high transduction efficiency, leading to high cell surface expression of CAR T cells. Using this protein, Arcellx creates drugs (modified T cells) that bind to target cells and kill them with improved specificity and increased binding affinity. The company's lead drug, anitokabtagene autoleucel, is undergoing clinical trials for patients with relapsed or refractory multiple myeloma and acute myeloid leukemia.
Founded: 2015
Website: https://www.arcellx.com/
Arcellx develops cell-based therapies for cancer treatment, based on immune cells that can be easily suppressed, activated and reprogrammed throughout the disease course. The company has developed D-domain - small, stable, fully synthetic binding protein with a hydrophobic core that serves as a chimeric antigen receptor, potentially enabling high transduction efficiency, leading to high cell surface expression of CAR T cells. Using this protein, Arcellx creates drugs (modified T cells) that bind to target cells and kill them with improved specificity and increased binding affinity. The company's lead drug, anitokabtagene autoleucel, is undergoing clinical trials for patients with relapsed or refractory multiple myeloma and acute myeloid leukemia.
